An Observational Study of Valcyte (Valganciclovir) in D+/R- Liver Transplant Recipients

Retrospective Review of Valganciclovir Efficacy in Preventing CMV Disease in D+/R- Liver Transplant Recipients - A Non-Interventional Program

This retrospective review will evaluate the efficacy of Valcyte (valganciclovir) in preventing Cytomegalovirus (CMV) disease in D+/R- liver transplant recipients. Data from eligible patients will be collected for the 6 months following transplantation.

Inclusion Criteria:

• Liver transplant recipients, >/= 16 years of age
• Transplantation between January 2004 and June 2009
• CMV seronegative recipient (R-) who received a liver transplant from a seropositive donor (D+)
• Valganciclovir therapy for at least 70 days beginning within 10 days post transplantation
• Assessment of CMV disease status within the first 6 months post transplantation

Exclusion Criteria:

• None